title: Central nervous system sites of the sleep promoting effects of eszopiclone in rats.
abstract: We examined the effects of eszopiclone (ESZ), a GABA-A receptor agonist in current clinical use as a hypnotic medication, on the activity of subcortical wake- and sleep-active neuronal populations in the rat brain. Sleep-wake states were quantified after i.p. injections of ESZ (3 and 10 mg/kg) or vehicle administered early in the dark phase, when rats are spontaneously awake. Rats were euthanized 2 h post-injection and brain tissue was processed for c-Fos protein immunoreactivity (IR) and for neurotransmitter markers. ESZ at 3 and 10 mg/kg increased time spent in non-rapid-eye-movement (nonREM) sleep, but had no significant effect on Fos-IR in GABAergic neurons in the preoptic hypothalamus that normally express c-Fos during sleep. Among wake-active cell types examined, Fos-IR in hypocretin (HCRT) neurons in the perifornical lateral hypothalamus (LH) was reduced following 3 and 10 mg/kg ESZ. At 10 mg/kg, ESZ suppressed Fos-IR in cholinergic and noncholinergic neurons in the basal forebrain and in serotonergic and nonserotonegic neurons in the dorsal raphe. Having determined that HCRT neurons were responsive to the low dose of systemic ESZ, we unilaterally perfused ESZ directly into the LH of awake rats, using reverse microdialysis. Perfusion of ESZ at 50 μM into the LH for 2 h suppressed waking-related Fos-IR in HCRT neurons, but not in nonHCRT neurons ipsilateral to the dialysis probe. Bilateral LH perfusion of ESZ at 50 μM for 2 h early in the dark phase significantly increased sleep. These findings demonstrate that sleep induction by ESZ does not require activation of GABAergic sleep-regulatory neurons in the preoptic hypothalamus, and identify suppression of HCRT neurons in the LH and suppression of basal forebrain and dorsal raphe neurons as potential mechanisms underlying the sleep-promoting effects of ESZ.
authors.affiliation: Research Service, V. A. Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
authors.forename: S
authors.initials: S
authors.lastname: Kumar
authors.forename: M N
authors.initials: MN
authors.lastname: Alam
authors.forename: S
authors.initials: S
authors.lastname: Rai
authors.forename: T
authors.initials: T
authors.lastname: Bashir
authors.forename: D
authors.initials: D
authors.lastname: McGinty
authors.forename: R
authors.initials: R
authors.lastname: Szymusiak
mesh_terms: D000818:Animals; D053961:Azabicyclo Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D000069582:Eszopiclone; D049690:History, Ancient; D006993:Hypnotics and Sedatives / Q000494:pharmacology* / Q000627:therapeutic use; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D008297:Male; D009479:Neuropeptides / Q000037:antagonists & inhibitors* / Q000502:physiology; D000068797:Orexins; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D012890:Sleep / Q000187:drug effects* / Q000502:physiology
chemical_list: D053961:Azabicyclo Compounds; D006993:Hypnotics and Sedatives; D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D000068797:Orexins; D010879:Piperazines; D000069582:Eszopiclone